Back
ESC2025 Premium Access

ACEi/ARB treatment in patients with myocardial infarction and preserved left ventricular ejection fraction does not confer a benefit: a target trial emulation

Session: Pharmacotherapy in coronary artery disease (1)
Topic: Pharmacotherapy
Speaker: Doctor A. Humphreys (Stockholm, SE)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Anna Humphreys

Karolinska Institute, Stockholm (Sweden)
0 follower

6 more presentations in this session

Baseline BMI and age modify cardiovascular benefits of GLP-1 receptor agonists

Speaker: Doctor C. Gibson (Boston, US)

Access
Abstract
Like
Thumbnail

The efficacy of 15mg of edoxaban on long-term outcome after PCI in patients with atrial fibrillation and high bleeding risk

Speaker: Doctor T. Sato (Narita, JP)

Access
Abstract
Like
Thumbnail

Long-term efficacy of endotype-based drug therapy on quality of life and symptom management in coronary vasomotion disorders

Speaker: Ms L. Saccardi (Stuttgart, DE)

Access
Abstract
Like
Thumbnail

Spironolactone and coronary atherosclerotic plaque modulation: insights from a serial coronary computed tomography angiography cohort study

Speaker: Doctor J. Zhang (Chengdu, CN)

Access
Abstract
Like
Thumbnail

Impact of 2nd-generation versus 3rd-generation beta-blockers on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range LVEF

Speaker: Doctor M. Susanti (Jawa Timur, ID)

Access
Abstract
Like
Thumbnail

Access the full session

Pharmacotherapy in coronary artery disease (1)

Speakers: Doctor A. Humphreys, Doctor C. Gibson, Doctor T. Sato, Ms L. Saccardi, Doctor J. Zhang...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources